Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade D 44.375 -2.04% -0.93
BHVN closed down 0.92 percent on Tuesday, July 16, 2019, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BHVN trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish -2.04%
Inside Day Range Contraction -2.04%
Upper Bollinger Band Touch Strength -2.04%
Crossed Above 200 DMA Bullish -2.94%
Crossed Above 20 DMA Bullish -2.94%
Wide Bands Range Expansion -2.94%
Wide Bands Range Expansion 4.36%
Bearish Engulfing Bearish 2.98%
180 Bearish Setup Bearish Swing Setup 2.98%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.98%

Older signals for BHVN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 15 Biohaven up 5% on publication of late-stage data on migraine med Zydis
Jul 15 Biohaven reveals positive results in migrane drug trial
Jul 15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
Jul 11 Biohaven's rimegepant successful in third late-stage migraine study
Jul 11 Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jul 11 Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
Jul 11 The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Jul 10 Biohaven +2.9% on positive migraine medicine data
Jul 10 Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
Jul 10 2 Single Hitters That Could Score With the 'Write' Strategy
See more BHVN news...
Indicators
Indicator Value
52 Week High 67.86
52 Week Low 29.17
Average Volume 1,099,342
200-Day Moving Average 45.0659
50-Day Moving Average 53.4562
20-Day Moving Average 42.6515
10-Day Moving Average 43.645
Average True Range 2.7501
ADX 24.1
+DI 20.9446
-DI 21.3716
Chandelier Exit (Long, 3 ATRs ) 55.9797
Chandelier Exit (Short, 3 ATRs ) 47.0103
Upper Bollinger Band 46.002
Lower Bollinger Band 39.301
Percent B (%b) 0.9
BandWidth 15.711054
MACD Line -2.5669
MACD Signal Line -3.383
MACD Histogram 0.816
Fundamentals Value
Market Cap 1.62 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -6.01
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.16
Resistance 3 (R3) 48.17 47.24 47.68
Resistance 2 (R2) 47.24 46.51 47.23 47.52
Resistance 1 (R1) 46.27 46.06 45.80 46.25 47.36
Pivot Point 45.33 45.33 45.10 45.32 45.33
Support 1 (S1) 44.36 44.60 43.90 44.35 43.24
Support 2 (S2) 43.43 44.15 43.42 43.08
Support 3 (S3) 42.46 43.43 42.92
Support 4 (S4) 42.44